Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenti-CCR5-KD
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrasynovial
01
Overview
lenti-CCR5-KD is an experimental gene therapy construct consisting of a lentiviral vector designed to deliver a short hairpin RNA (shRNA) sequence that targets and knocks down the expression of the C-C chemokine receptor type 5 (CCR5). In the context of rheumatoid arthritis (RA) research, this agent is used to investigate the role of the ORM1-CCR5 signaling axis in the pathogenesis of the disease. By reducing CCR5 levels in fibroblast-like synoviocytes (FLS), lenti-CCR5-KD inhibits the aggressive cellular phenotype characterized by excessive proliferation, migration, and invasion. This intervention aims to alleviate synovial hyperplasia and reduce the inflammatory response in the joints, suggesting a potential therapeutic strategy for RA.
- Other names
- lentiviral CCR5 knockdown vectorshCCR5 lentivirusshCCR-5 lentivirusshCCR 5 lentivirusCCR5-shRNA lentivirusCCR-5-shRNA lentivirusCCR 5-shRNA lentivirus
02
Targets
CCR5 (C-C chemokine receptor type 5)
Beyond the preview
Go deeper on lenti-CCR5-KD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenti-CCR5-KD.